1. Home
  2. VTAK vs QNRX Comparison

VTAK vs QNRX Comparison

Compare VTAK & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTAK
  • QNRX
  • Stock Information
  • Founded
  • VTAK 2002
  • QNRX 2018
  • Country
  • VTAK United States
  • QNRX United States
  • Employees
  • VTAK N/A
  • QNRX N/A
  • Industry
  • VTAK Medical/Dental Instruments
  • QNRX Medical/Dental Instruments
  • Sector
  • VTAK Health Care
  • QNRX Health Care
  • Exchange
  • VTAK Nasdaq
  • QNRX Nasdaq
  • Market Cap
  • VTAK 3.1M
  • QNRX 3.3M
  • IPO Year
  • VTAK 2018
  • QNRX N/A
  • Fundamental
  • Price
  • VTAK $0.30
  • QNRX $8.70
  • Analyst Decision
  • VTAK
  • QNRX
  • Analyst Count
  • VTAK 0
  • QNRX 0
  • Target Price
  • VTAK N/A
  • QNRX N/A
  • AVG Volume (30 Days)
  • VTAK 41.4M
  • QNRX 21.0K
  • Earning Date
  • VTAK 08-13-2025
  • QNRX 08-07-2025
  • Dividend Yield
  • VTAK N/A
  • QNRX N/A
  • EPS Growth
  • VTAK N/A
  • QNRX N/A
  • EPS
  • VTAK N/A
  • QNRX N/A
  • Revenue
  • VTAK $481,000.00
  • QNRX N/A
  • Revenue This Year
  • VTAK $822.86
  • QNRX N/A
  • Revenue Next Year
  • VTAK $168.42
  • QNRX N/A
  • P/E Ratio
  • VTAK N/A
  • QNRX N/A
  • Revenue Growth
  • VTAK 9.57
  • QNRX N/A
  • 52 Week Low
  • VTAK $0.16
  • QNRX $5.01
  • 52 Week High
  • VTAK $8.40
  • QNRX $54.95
  • Technical
  • Relative Strength Index (RSI)
  • VTAK 50.43
  • QNRX 56.56
  • Support Level
  • VTAK $0.25
  • QNRX $8.00
  • Resistance Level
  • VTAK $0.38
  • QNRX $8.58
  • Average True Range (ATR)
  • VTAK 0.07
  • QNRX 0.44
  • MACD
  • VTAK 0.01
  • QNRX -0.08
  • Stochastic Oscillator
  • VTAK 18.46
  • QNRX 53.85

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: